| People with diabetes |
Facilitating patient–clinician interaction when discussing glucose‐lowering interventions that affect risk of hypoglycaemia Assessment of risk of hypoglycaemia at the individual level More support in relationships with partners, family members, co‐workers and friends Better appreciation of indirect costs of (non‐severe) hypoglycaemia, such as overall functioning, sleep, well‐being, quality of life, productivity and work‐related absenteeism and presenteeism Advancement of personalised glucose management
|
| Healthcare professionals |
Improved knowledge of clinical and psychological impact of hypoglycaemia (at various levels) Better appreciation of trial outcomes More insight into the pathways underlying hypoglycaemia‐sensing and impaired awareness of hypoglycaemia Equipped healthcare professionals better to discuss treatment choices with people with diabetes and their family members
|
| Payers |
Calculation of the overall costs of the hypoglycaemic burden Enabling more accurate cost‐effectiveness of interventions aimed at improving glucose control Help with directing resources to where they can be used the most efficiently
|
| Regulatory authorities |
Better understanding of the clinical, psychological and health‐economic impact of hypoglycaemia, and of valid assessment tools Facilitating the conduct and use of meta‐analyses to compare both efficacy and (hypoglycaemic) safety of glucose‐lowering interventions Providing strong evidence base for development of guidelines and its adoption by other stakeholders, including payers
|
| Scientific community |
Further delineation of mechanisms underlying the link between hypoglycaemia and cardiovascular risks Setting the standard for glucose levels to be used in experimental hypoglycaemia research (e.g. clamps) Invitation to scientists to use the constructed Hypo‐RESOLVE database to answer new research questions
|
| Industry |
Enabling better comparisons of glucose‐lowering interventions and strategies across trials and benchmarking industry's products against those of competitors Harmonization of hypoglycaemia measures by SMBG or CGM will inform the industry how to best apply CGM in future clinical trials Discovering new targets for intervention will open avenues for the development of novel hypoglycaemic risk reducing pharmaceutical agents and technological solutions Helping to better define populations most in need of hypoglycaemia risk reducing interventions in clinical trials
|
